Tag Archives: biotech

Throughout December last year, Insys Therapeutics Inc (NASDAQ:INSY) flat lined around $9 a share. Despite continued effort by management to maintain a positive news flow, and in turn, to buoy positive sentiment, the company couldn’t break...

RenovaCare Inc (OTCMKTS:RCAR) is running this week, on what looks to be very little in the way of fundamental developments. When this sort of thing happens, we always take a closer look in an attempt to figure out why it is moving, and if –...

At the beginning of February, we published this article on Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX), noting the upside momentum seen during the period running up to our coverage, and attempting to ascertain whether this action was a one-off...

X T L Biopharmaceuticals Ltd (ADR) (NASDAQ:XTLB) is an interesting one. The company is a biotechnology entity based out of Israel but trading on the NASDAQ by way of the ADS system. It fell below minimum bid requirements for the final quarter...

Our regular readers will know that Peregrine Pharmaceuticals (NASDAQ:PPHM) is one of the companies we have long highlighted as one that we see as being undervalued, and by proxy, due a revaluation. On a number of occasions over the last few...

Zenosense Inc (OTCMKTS:ZENO) spent the first half of 2016 essentially flat, trading in and around the $0.02 mark. It picked up some strength during the second half of the year, boosting to a little above the $0.1 level, but remained flat at...

At the end of January, Novan Inc (NASDAQ:NOVN) published data from its lead acne trials, and the company took a severe hit on the back of the numbers. From a PPS of around $20, markets traded Novan down to less than $5 a share, pushing the...

Back in December 2016, we looked at Neurotrope Inc (OTCMKTS:NTRP) as part of this coverage. We noted that the company had just taken a hit on the announcing of a private placement, and that (as we see so often in biotech) the market response...

Matinas BioPharma Holdings Inc (OTCMKTS:MTNB) put out a business outlook at the end of January, and alongside the outlook, gave markets a number of milestones to keep an eye on across the coming twelve months. This is one we’ve looked at...

On the release of some data early this week Zosano Pharma Corp (NASDAQ:ZSAN) ran up more than 75%, and a small correction aside, has held on to the majority of these gains for the subsequent forty eight hours. At time of writing, US afternoon...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter